Resource Summary Report

Generated by NIF on Sep 20, 2026

CAMA-1

RRID:CVCL_1115
Type: Cell Line

Proper Citation

RRID:CVCL_1115

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1115

Proper Citation: RRID:CVCL_1115

Description: Cell line CAMA-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: PMID:833871, PMID:924690, PMID:3518877, PMID:6582512, PMID:6935474, PMID:7017212, PMID:7459858, PMID:10862037, PMID:11343771, PMID:12353263, PMID:12661003, PMID:12800145, PMID:16397213, PMID:16541312, PMID:17157791, PMID:18516279, PMID:19593635, PMID:20164919, PMID:20215515, PMID:22460905, PMID:22585861, PMID:23601657, PMID:24094812, PMID:24162158, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30894373, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CAMA-1

Synonyms: Cama-1, CAMA1, CAMA

Cross References: BTO:BTO_0005022, CLO:CLO_0002194, EFO:EFO_0001100, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-21, BioGRID_ORCS_Cell_line:588, BioSample:SAMN03472698, BioSample:SAMN10987851, cancercelllines:CVCL_1115, CancerTools:161925, Cell_Model_Passport:SIDM00920, ChEMBL-Cells:CHEMBL3308719, ChEMBL-Targets:CHEMBL1075416, Cosmic:687468, Cosmic:871153, Cosmic:904354, Cosmic:946382, Cosmic:997930, Cosmic:1000130, Cosmic:1046925, Cosmic:1047717, Cosmic:1136349, Cosmic:1287905, Cosmic:1289386, Cosmic:1603195, Cosmic:1995361, Cosmic:2165018, Cosmic:2750520, Cosmic-CLP:946382, DepMap:ACH-000783, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:946382, GEO:GSM344344, GEO:GSM344394, GEO:GSM378143, GEO:GSM421864, GEO:GSM783930, GEO:GSM827295, GEO:GSM843488, GEO:GSM843489, GEO:GSM847248, GEO:GSM847458, GEO:GSM886917, GEO:GSM887983, GEO:GSM984230, GEO:GSM1008894, GEO:GSM1053694, GEO:GSM1172856, GEO:GSM1172948, GEO:GSM1215264, GEO:GSM1238119, GEO:GSM1374437, GEO:GSM1661977, GEO:GSM1669660, IARC_TP53:18372, LiGeA:CCLE_527, LINCS_HMS:50131, LINCS_LDP:LCL-1466, Lonza:1251, PharmacoDB:CAMA1_181_2019, PRIDE:PXD002486, PRIDE:PXD030304, Progenetix:CVCL_1115, PubChem_Cell_line:CVCL_1115, SLKBase:3405, Wikidata:Q54808432

ID: CVCL_1115

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260920T001727+0000

Ratings and Alerts

No rating or validation information has been found for CAMA-1.

No alerts have been found for CAMA-1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. Cell chemical biology, 33(6), 785.

Sottnik JL, et al. (2026) Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling. bioRxiv : the preprint server for biology.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. Cell reports. Medicine, 7(7), 102922.

Wang H, et al. (2026) ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes. Cancer research, 86(1), 116.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Bartkowiak K, et al. (2025) Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients. Scientific reports, 15(1), 3913.

Medina EF, et al. (2025) System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells. Cell reports. Medicine, 6(11), 102425.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

Chen W, et al. (2025) Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding. Cancer discovery.

Armand J, et al. (2025) Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. eLife, 14.

Minati R, et al. (2025) CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling. Cell reports, 44(12), 116676.

Boettcher L, et al. (2025) Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer. Breast cancer research : BCR, 27(1), 137.

Albrecht J, et al. (2024) Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance. Molecular oncology.

Yu J, et al. (2024) Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. Cell, 187(17), 4713.

Przanowska RK, et al. (2024) Patient-derived response estimates from zero-passage organoids of luminal breast cancer. Breast cancer research : BCR, 26(1), 192.

Toader D, et al. (2023) Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Molecular cancer therapeutics, 22(9), 999.

Jamal K, et al. (2022) Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. Cancer research communications, 2(10), 1244.

Aka Y, et al. (2021) Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target. The international journal of biochemistry & cell biology, 137, 106028.

Zhu C, et al. (2021) Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1. Cell reports, 34(7), 108749.